Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a rights issue and a directed issue of in total 1,499,673,033 shares. The share issues has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of 31 March 2024, the total number of shares and votes in the Company amounts to 1,529,483,397. The Company's registered share capital amounts to approximately SEK 342,888,859.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-04-01 08:30 CEST.

Attachments

Change of number of shares and votes in Xbrane

© Modular Finance, source Nordic Press Releases